Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:DVAXNASDAQ:FOLDNASDAQ:GERNNASDAQ:LGND On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeDVAXDynavax Technologies$13.69-0.4%$13.09$9.74▼$14.63$1.70B1.232.25 million shs1.08 million shsFOLDAmicus Therapeutics$8.81-0.9%$9.40$8.55▼$12.65$2.71B0.692.35 million shs1.67 million shsGERNGeron$1.67-5.6%$2.66$1.46▼$5.34$1.06B0.5315.18 million shs11.83 million shsLGNDLigand Pharmaceuticals$105.62-2.3%$114.44$67.72▼$129.90$2.03B1.12124,013 shs120,884 shs5G Stocks: The Path Forward is ProfitableEnter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceDVAXDynavax Technologies-0.36%-4.53%+7.80%+5.63%+12.49%FOLDAmicus Therapeutics-0.90%-2.33%-7.94%-5.88%-25.40%GERNGeron-5.65%-2.91%-40.14%-56.74%-4.57%LGNDLigand Pharmaceuticals-2.29%-8.95%-6.34%-9.66%+45.16%Remove AdsCompare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationDVAXDynavax Technologies4.2086 of 5 stars3.23.00.04.71.11.71.9FOLDAmicus Therapeutics4.0243 of 5 stars3.41.00.04.32.60.81.9GERNGeron4.3803 of 5 stars4.43.00.01.32.93.30.6LGNDLigand Pharmaceuticals4.6958 of 5 stars3.54.00.04.42.82.51.9Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceDVAXDynavax Technologies 2.33Hold$21.5057.05% UpsideFOLDAmicus Therapeutics 2.78Moderate Buy$16.7590.12% UpsideGERNGeron 2.83Moderate Buy$5.68240.23% UpsideLGNDLigand Pharmaceuticals 3.00Buy$147.0039.18% UpsideCurrent Analyst Ratings BreakdownLatest GERN, FOLD, LGND, and DVAX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails3/12/2025GERNGeronHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Neutral3/12/2025GERNGeronNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$5.00 ➝ $5.002/27/2025GERNGeronBarclaysSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight$9.00 ➝ $4.002/27/2025GERNGeronScotiabankSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetSector Outperform ➝ Sector Outperform$6.00 ➝ $4.002/27/2025GERNGeronStifel NicolausSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$8.00 ➝ $4.002/27/2025GERNGeronNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$7.00 ➝ $5.002/27/2025GERNGeronB. RileySubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeBuy ➝ Neutral$3.50 ➝ $2.002/26/2025GERNGeronHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeBuy ➝ Neutral2/21/2025DVAXDynavax TechnologiesWilliam BlairSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform2/21/2025DVAXDynavax TechnologiesHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$31.00 ➝ $31.002/20/2025FOLDAmicus TherapeuticsWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$18.00 ➝ $17.00(Data available from 3/14/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookDVAXDynavax Technologies$277.25M6.13N/AN/A$4.81 per share2.85FOLDAmicus Therapeutics$528.30M5.12N/AN/A$0.63 per share13.98GERNGeron$76.99M13.81N/AN/A$0.46 per share3.63LGNDLigand Pharmaceuticals$167.13M12.17$4.33 per share24.39$40.39 per share2.62Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateDVAXDynavax Technologies-$6.39M$0.1876.0627.94N/A9.85%4.22%2.67%5/14/2025 (Estimated)FOLDAmicus Therapeutics-$151.58M-$0.18N/A20.491.51-10.62%12.44%2.60%5/8/2025 (Estimated)GERNGeron-$184.13M-$0.27N/AN/AN/A-682.48%-67.53%-45.46%5/1/2025 (Estimated)LGNDLigand Pharmaceuticals$52.15M-$0.1642.0828.47N/A29.68%4.95%4.39%5/6/2025 (Estimated)Latest GERN, FOLD, LGND, and DVAX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails2/26/2025Q4 2024GERNGeron-$0.04-$0.04N/A-$0.04$45.29 million$47.54 million2/20/2025Q4 2024DVAXDynavax Technologies$0.05$0.05N/A$0.05$72.70 million$72.03 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthDVAXDynavax TechnologiesN/AN/AN/AN/AN/AFOLDAmicus TherapeuticsN/AN/AN/AN/AN/AGERNGeronN/AN/AN/AN/AN/ALGNDLigand PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioDVAXDynavax Technologies0.3313.2312.34FOLDAmicus Therapeutics2.013.392.42GERNGeron0.042.892.74LGNDLigand PharmaceuticalsN/A12.4911.81Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipDVAXDynavax Technologies96.96%FOLDAmicus TherapeuticsN/AGERNGeron73.71%LGNDLigand Pharmaceuticals91.28%Insider OwnershipCompanyInsider OwnershipDVAXDynavax Technologies2.98%FOLDAmicus Therapeutics2.20%GERNGeron3.00%LGNDLigand Pharmaceuticals5.90%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableDVAXDynavax Technologies350124.07 million127.54 millionOptionableFOLDAmicus Therapeutics480307.24 million292.23 millionOptionableGERNGeron70636.90 million585.76 millionOptionableLGNDLigand Pharmaceuticals8019.26 million17.78 millionOptionableGERN, FOLD, LGND, and DVAX HeadlinesRecent News About These CompaniesBank of New York Mellon Corp Sells 4,847 Shares of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND)March 13 at 3:06 AM | marketbeat.comCallan Family Office LLC Takes Position in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND)March 12 at 3:52 AM | marketbeat.comLigand Pharmaceuticals (NASDAQ:LGND) Stock Rating Lowered by StockNews.comMarch 12 at 1:19 AM | americanbankingnews.comLigand Pharmaceuticals (NASDAQ:LGND) Downgraded by StockNews.com to "Sell"March 11 at 11:03 PM | marketbeat.comBarclays Keeps Their Buy Rating on Ligand Pharma (LGND)March 10, 2025 | markets.businessinsider.comEssex Investment Management Co. LLC Sells 3,901 Shares of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND)March 10, 2025 | marketbeat.comLisanti Capital Growth LLC Has $4.18 Million Holdings in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND)March 8, 2025 | marketbeat.comOctavio Espinoza Sells 5,000 Shares of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) StockMarch 7, 2025 | marketbeat.comLigand Pharmaceuticals Incorporated (NASDAQ:LGND) CFO Sells $575,150.00 in StockMarch 7, 2025 | insidertrades.comDana Investment Advisors Inc. Sells 4,373 Shares of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND)March 6, 2025 | marketbeat.comCookson Peirce & Co. Inc. Purchases 2,755 Shares of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND)March 6, 2025 | marketbeat.comFisher Asset Management LLC Increases Stake in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND)March 5, 2025 | marketbeat.comBrokerages Set Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) PT at $147.00March 5, 2025 | americanbankingnews.comLigand Pharmaceuticals (NASDAQ:LGND) Trading Down 8.8% - Here's WhyMarch 4, 2025 | marketbeat.comLGND: First Steps into Cell & Gene TherapyMarch 3, 2025 | msn.comLigand Pharma (LGND) Receives a Buy from RBC CapitalMarch 3, 2025 | markets.businessinsider.comLigand to Participate in March Investor ConferencesMarch 3, 2025 | globenewswire.comLigand Pharmaceuticals Incorporated (NASDAQ:LGND) Given Average Recommendation of "Buy" by BrokeragesMarch 2, 2025 | marketbeat.comPrincipal Financial Group Inc. Purchases 6,382 Shares of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND)March 1, 2025 | marketbeat.comLigand Pharmaceuticals’ Earnings Call Highlights Strong GrowthFebruary 28, 2025 | tipranks.comLigand Pharmaceuticals (NASDAQ:LGND) Trading Up 7.3% - Should You Buy?February 28, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeGERN, FOLD, LGND, and DVAX Company DescriptionsDynavax Technologies NASDAQ:DVAX$13.69 -0.05 (-0.36%) Closing price 03/13/2025 04:00 PM EasternExtended Trading$13.72 +0.03 (+0.18%) As of 03/13/2025 05:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe. The company also manufactures and sells CpG 1018, the adjuvant used in HEPLISAV-B. Dynavax Technologies Corporation has a collaboration agreement with Valneva Scotland Limited; Zhejiang Clover Biopharmaceuticals, Inc.; Clover Biopharmaceuticals (Hong Kong) Co., Limited; Biological E. Limited; PT Bio Farma; Medigen Vaccine Biologics; and Serum Institute of India Pvt. Ltd. The company was formerly known as Double Helix Corporation and changed its name to Dynavax Technologies Corporation in September 1996. The company was incorporated in 1996 and is headquartered in Emeryville, California.Amicus Therapeutics NASDAQ:FOLD$8.81 -0.08 (-0.90%) Closing price 03/13/2025 04:00 PM EasternExtended Trading$8.80 -0.01 (-0.06%) As of 03/13/2025 04:41 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset. It has collaboration and license agreements with the University of Pennsylvania to research and develop parvovirus gene therapy products; and GlaxoSmithKline. Amicus Therapeutics, Inc. was incorporated in 2002 and is headquartered in Princeton, New Jersey.Geron NASDAQ:GERN$1.67 -0.10 (-5.65%) Closing price 03/13/2025 04:00 PM EasternExtended Trading$1.69 +0.02 (+1.14%) As of 03/13/2025 07:41 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in myeloid hematologic malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis. The company was incorporated in 1990 and is headquartered in Foster City, California.Ligand Pharmaceuticals NASDAQ:LGND$105.62 -2.47 (-2.29%) Closing price 03/13/2025 04:00 PM EasternExtended Trading$105.52 -0.09 (-0.09%) As of 03/13/2025 04:20 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, engages in the development and licensing of biopharmaceutical assets worldwide. Its commercial programs include Kyprolis and Evomela, which are used to treat multiple myeloma; Rylaze, a recombinant erwinia asparaginase for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma in adult and pediatric patients; Filspari, a dual endothelin and angiotensin II receptor antagonist in development for rare kidney diseases and non-immunosuppressive treatment indicated for immunoglobulin A nephropathy; Teriparatide injection product for osteoporosis; Vaxneuvance for the prevention of invasive disease caused by streptococcus pneumoniae serotypes; and Pneumosil, a pneumococcal conjugate vaccine to help fight against pneumococcal pneumonia among children. The company also offers TZIELD, a CD3-directed antibody indicated to delay the onset of Stage 3 type 1 diabetes (T1D) in adults and children aged 8 years and older with Stage 2 T1D; Nexterone, a captisol-enabled formulation of amiodarone; Zulresso, a captisol-enabled formulation of brexanolone for the treatment of postpartum depression; and Veklury, an antiviral treatment for moderate or severe COVID-19. In addition, it provides Noxafil-IV, a captisol-enabled formulation of posaconazole for IV use; Duavee for the treatment of post-menopausal symptoms in women; Exemptia for autoimmune diseases; Vivitra for breast cancer; and Bryxta and Zybev for various indications. The company has alliances, licenses, and other business relationships with Amgen, Merck, Pfizer, Jazz, Takeda, Gilead Sciences, and Baxter International. Further, it sells Captisol materials. Ligand Pharmaceuticals Incorporated was incorporated in 1987 and is based in Jupiter, Florida. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Is a Bottom Finally Forming in Rocket Lab Stock? Intel Stock Surges on New CEO – The Real Story Runs Deeper AMD Stock: Can the PC Refresh Cycle Spark a Rally? Ramaco Resources Pins Hopes on Coal's Untapped Potential Nu Holdings: Is Brazil’s Fintech Leader a Buy at This Discount? Beyond a Market Correction, Moves to Make Now NVIDIA Stock Remains Stunningly Undervalued—Here’s Why Market Overreacts, But Guidewire’s Growth Story Remains Strong Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
